导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.14% | 2226/4773 |
| 近一周 | -3.73% | 4513/5461 |
| 近一月 | -10.70% | 5176/5420 |
| 近一季 | -21.04% | 4987/5208 |
| 近半年 | -2.18% | 1804/4919 |
| 近一年 | 5.49% | 1592/4366 |
| 近两年 | 116.12% | 425/2954 |
| 近三年 | 76.25% | 243/2253 |
| 成立以来 | 137.23% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.27% 2216/4961 |
36.35% 898/5312 |
- - |
- - |
| 2025 | 54.89% 345/4813 |
-3.42% 3053/3635 |
3.97% 892/4076 |
55.12% 188/4524 |
-0.56% 2543/4813 |
| 2024 | 20.57% 457/3463 |
-1.57% 1243/2808 |
-6.05% 1838/3014 |
30.68% 129/3129 |
-0.23% 1352/3463 |
| 2023 | -21.87% 1912/2656 |
-0.61% 1807/2280 |
-7.59% 1869/2385 |
-9.91% 1908/2515 |
-5.58% 1404/2655 |
| 2022 | -28.15% 1534/2207 |
-19.49% 1464/1919 |
6.58% 658/2016 |
-18.77% 1733/2113 |
3.07% 776/2208 |
| 2021 | 16.17% 278/1822 |
-5.75% 953/1255 |
30.07% 42/1330 |
-6.41% 925/1466 |
1.25% 973/1822 |
| 2020 | 85.71% 30/1250 |
5.73% 51/1028 |
33.85% 26/1067 |
9.50% 645/1164 |
19.84% 67/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 交银创业板50指数A VS. 长安沪深300非周期A(740101) |